IL6 and inflammatory bowel disease: With the effective and safe intervention of olamkicept, a selective IL-6 trans-signaling blocker, for IBD, another disease process for which this signaling mechanism is involved, the stage is set to re-purpose this pharmaceutical preparation for clinical trials in patients at high risk for the development of PNDs.